home / stock / galt / galt quote
Last: | $2.14 |
---|---|
Change Percent: | 3.88% |
Open: | $2.05 |
Close: | $2.06 |
High: | $2.2 |
Low: | $2.05 |
Volume: | 31,341 |
Last Trade Date Time: | 07/08/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.14 | $2.05 | $2.06 | $2.2 | $2.05 | 31,341 | 07-08-2024 |
$2.06 | $2.18 | $2.06 | $2.18 | $2 | 582,454 | 07-05-2024 |
$2.15 | $2.29 | $2.15 | $2.3 | $2.15 | 161,511 | 07-04-2024 |
$2.15 | $2.29 | $2.15 | $2.3 | $2.15 | 161,511 | 07-03-2024 |
$2.28 | $2.34 | $2.28 | $2.5 | $2.27 | 153,948 | 07-02-2024 |
$2.35 | $2.27 | $2.35 | $2.36 | $2.205 | 137,641 | 07-01-2024 |
$2.26 | $2.23 | $2.26 | $2.39 | $2.17 | 2,417,631 | 06-28-2024 |
$2.2 | $2.2 | $2.2 | $2.3499 | $2.1 | 173,407 | 06-27-2024 |
$2.22 | $2.21 | $2.22 | $2.26 | $2.02 | 196,115 | 06-26-2024 |
$2.23 | $2.13 | $2.23 | $2.37 | $2.13 | 192,604 | 06-25-2024 |
$2.13 | $2.33 | $2.13 | $2.4 | $2.09 | 218,123 | 06-24-2024 |
$2.34 | $2.44 | $2.34 | $2.4869 | $2.275 | 187,335 | 06-21-2024 |
$2.42 | $2.34 | $2.42 | $2.4201 | $2.31 | 113,498 | 06-20-2024 |
$2.33 | $2.58 | $2.33 | $2.58 | $2.32 | 128,532 | 06-19-2024 |
$2.33 | $2.58 | $2.33 | $2.58 | $2.32 | 128,532 | 06-18-2024 |
$2.5 | $2.63 | $2.5 | $2.665 | $2.5 | 125,544 | 06-17-2024 |
$2.62 | $2.66 | $2.62 | $2.73 | $2.61 | 54,580 | 06-14-2024 |
$2.66 | $2.74 | $2.66 | $2.7997 | $2.65 | 145,562 | 06-13-2024 |
$2.73 | $2.65 | $2.73 | $2.76 | $2.58 | 114,269 | 06-12-2024 |
$2.62 | $2.685 | $2.62 | $2.75 | $2.56 | 189,943 | 06-11-2024 |
News, Short Squeeze, Breakout and More Instantly...
Galectin Therapeutics Inc. Company Name:
GALT Stock Symbol:
NASDAQ Market:
Galectin Therapeutics Inc. Website:
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024...
Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) NAVIGATE trial remains on track for interim top-lin...
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be attending and presenting at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference. Detai...